A first-in-class intravenous kappa opioid receptor (KOR) agonist, an oral soluble guanylate cyclase (sGC) stimulator, a first-in-class subcutaneous complement C3 inhibitor, and an oral contraceptive comprising a synthetic progesterone (drospirenone) and a plant-based estrogen (estetrol) make up the final group of novel drugs from 2021 that we didn’t cover in our other indication-specific reviews. In 2021, the FDA approved four new drugs for various other indications, from rare diseases to pregnancy prevention.
This article and slide deck explores each in more detail, including but not limited to their:
- mechanisms of action
- target rationale
- disease context
- original patents
- key clinical data
- industry history
request a trial
You don’t have time to read everything, but you can’t afford to fall behind.
Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.
Get ahead now by requesting a trial.
